Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres

Jun Young Seo, Seung Yong Seong, Byung-Yoon Ahn, Ick Chan Kwon, Hesson Chung, Seo Young Jeong

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.

Original languageEnglish
Pages (from-to)1143-1149
Number of pages7
JournalInfection and Immunity
Volume70
Issue number3
DOIs
Publication statusPublished - 2002 Mar 4

Fingerprint

Microspheres
Immunity
Immunization
Cholera Toxin
Streptococcus pneumoniae
Immune System
Pneumococcal Infections
Pneumococcal Vaccines
Antibody Formation
Sepsis
Acquired Immunodeficiency Syndrome
Vaccines
HIV
Lung
Serogroup

ASJC Scopus subject areas

  • Immunology

Cite this

Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. / Seo, Jun Young; Seong, Seung Yong; Ahn, Byung-Yoon; Kwon, Ick Chan; Chung, Hesson; Jeong, Seo Young.

In: Infection and Immunity, Vol. 70, No. 3, 04.03.2002, p. 1143-1149.

Research output: Contribution to journalArticle

Seo, Jun Young ; Seong, Seung Yong ; Ahn, Byung-Yoon ; Kwon, Ick Chan ; Chung, Hesson ; Jeong, Seo Young. / Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres. In: Infection and Immunity. 2002 ; Vol. 70, No. 3. pp. 1143-1149.
@article{2dac7efa1c334cb385f72c709e9ef9cf,
title = "Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres",
abstract = "The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.",
author = "Seo, {Jun Young} and Seong, {Seung Yong} and Byung-Yoon Ahn and Kwon, {Ick Chan} and Hesson Chung and Jeong, {Seo Young}",
year = "2002",
month = "3",
day = "4",
doi = "10.1128/IAI.70.3.1143-1149.2002",
language = "English",
volume = "70",
pages = "1143--1149",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin A encapsulated in microspheres

AU - Seo, Jun Young

AU - Seong, Seung Yong

AU - Ahn, Byung-Yoon

AU - Kwon, Ick Chan

AU - Chung, Hesson

AU - Jeong, Seo Young

PY - 2002/3/4

Y1 - 2002/3/4

N2 - The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.

AB - The global use of a capsular polysaccharide-based pneumococcal vaccine has been limited because of serotype-specific protection and poor effectiveness in individuals with low immunocompetency. The mucosal immune system develops earlier in infants and lasts longer in the elderly than does the systemic immune system. Furthermore, mucosal immunization is beneficial for AIDS patients, because human immunodeficiency virus-infected subjects can develop normal mucosal antibody responses even in late clinical phases. For these reasons, we evaluated recombinant pneumococcal surface adhesin A (rPsaA) of Streptococcus pneumoniae in terms of cross-protective immune responses after oral delivery. Encapsulated rPsaA provided higher immunogenicity than naked rPsaA. Coencapsulation or codelivery of the cholera toxin (CT) B subunit (CTB) and CT also increased the immunogenicity of rPsaA. Cross-protective immunities against five strains of S. pneumoniae (types 4, 6B, 14, 19F, and 23F) were induced after oral immunization with microencapsulated rPsaA. Lung colonization and septicemia caused by the five serotypes were significantly inhibited by oral immunization with microencapsulated rPsaA. These results suggest that rPsaA coencapsulated with CTB can be used as an oral vaccine to induce cross-protective immunity for the prevention of pneumococcal infection.

UR - http://www.scopus.com/inward/record.url?scp=0036176042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036176042&partnerID=8YFLogxK

U2 - 10.1128/IAI.70.3.1143-1149.2002

DO - 10.1128/IAI.70.3.1143-1149.2002

M3 - Article

C2 - 11854194

AN - SCOPUS:0036176042

VL - 70

SP - 1143

EP - 1149

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 3

ER -